Immuneering (IMRX) Shares Outstanding (Weighted Average) (2020 - 2026)

Immuneering's Shares Outstanding (Weighted Average) history runs 7 years deep, the most recent figure standing at $64.7 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 81.99% year-over-year to $64.7 million; the TTM figure through Mar 2026 stood at $64.7 million (up 81.99% YoY), while the FY2025 annual figure was $44.0 million, up 46.8% from the prior year.
• Shares Outstanding (Weighted Average) was $64.7 million for Q1 2026 at Immuneering, up from $44.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $64.7 million in Q1 2026 to a low of $26.4 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $32.6 million across 5 years, with a median of $29.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) jumped 432.53% in 2022, then rose 0.32% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $26.4 million in 2022, then rose by 7.69% to $28.4 million in 2023, then gained by 5.51% to $30.0 million in 2024, then soared by 46.8% to $44.0 million in 2025, then jumped by 46.91% to $64.7 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $64.7 million (Q1 2026), $44.0 million (Q4 2025), and $37.1 million (Q3 2025), per Business Quant data.